RTW Investments LP boosted its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 64.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 878,452 shares of the medical instruments supplier’s stock after purchasing an additional 342,745 shares during the period. OraSure Technologies makes up 2.8% of RTW Investments LP’s investment portfolio, making the stock its 11th largest holding. RTW Investments LP owned about 1.45% of OraSure Technologies worth $16,568,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the business. Osterweis Capital Management Inc. purchased a new stake in OraSure Technologies in the fourth quarter valued at approximately $4,621,000. ETRADE Capital Management LLC grew its stake in OraSure Technologies by 43.4% during the fourth quarter. ETRADE Capital Management LLC now owns 18,402 shares of the medical instruments supplier’s stock worth $347,000 after buying an additional 5,566 shares during the period. Kennedy Capital Management Inc. purchased a new stake in OraSure Technologies during the fourth quarter worth approximately $6,881,000. Landscape Capital Management L.L.C. purchased a new stake in OraSure Technologies during the fourth quarter worth approximately $581,000. Finally, Allianz Asset Management GmbH lifted its position in shares of OraSure Technologies by 4,140.9% during the fourth quarter. Allianz Asset Management GmbH now owns 403,096 shares of the medical instruments supplier’s stock worth $7,602,000 after purchasing an additional 393,591 shares in the last quarter. 93.67% of the stock is currently owned by institutional investors.
In related news, Director Stephen S. Phd Tang sold 23,333 shares of OraSure Technologies stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the transaction, the director now directly owns 59,749 shares of the company’s stock, valued at $1,073,689.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brian Smith sold 20,000 shares of OraSure Technologies stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $17.97, for a total value of $359,400.00. Following the completion of the sale, the executive vice president now owns 28,075 shares of the company’s stock, valued at $504,507.75. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by company insiders.
OraSure Technologies, Inc. (NASDAQ OSUR) traded down $0.14 during midday trading on Wednesday, hitting $18.46. 372,798 shares of the stock were exchanged, compared to its average volume of 647,442. OraSure Technologies, Inc. has a 1-year low of $10.75 and a 1-year high of $23.01. The stock has a market capitalization of $1,129.72, a price-to-earnings ratio of 36.47, a price-to-earnings-growth ratio of 5.17 and a beta of 1.60.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. The company had revenue of $52.00 million for the quarter, compared to the consensus estimate of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. The company’s revenue for the quarter was up 46.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.13 earnings per share. analysts anticipate that OraSure Technologies, Inc. will post 0.29 EPS for the current fiscal year.
OSUR has been the topic of a number of recent research reports. BidaskClub raised shares of OraSure Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 20th. Zacks Investment Research raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a report on Saturday, December 30th. ValuEngine raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $24.00 target price on shares of OraSure Technologies in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $22.25.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2018/03/14/orasure-technologies-inc-osur-stake-increased-by-rtw-investments-lp.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.